|
|
| | UFP-101 Basic information |
| Product Name: | UFP-101 | | Synonyms: | UFP-101;N-(BZL)GLY-GLY-GLY-PHE-THR-GLY-ALA-ARG-LYS-SER-ALA-ARG-LYS-ARG-LYS-ASN-GLN-NH2;[NPHE1, ARG14, LYS15]NOCICEPTIN-NH2;N-(Bzl)Gly-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Arg-Lys-Asn-Gln-NH2 (N-(Bzl)GlyN-Benzylglycine);PubChem ID: 16152632;L-Glutamamide, N-(phenylmethyl)glycylglycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-arginyl-L-lysyl-L-asparaginyl- (9CI) | | CAS: | 849024-68-6 | | MF: | C82H138N32O21 | | MW: | 1908.17 | | EINECS: | | | Product Categories: | Opioid receptor and opioid-like receptor | | Mol File: | Mol File |  |
| | UFP-101 Chemical Properties |
| storage temp. | Desiccate at -20°C | | form | Powder | | Water Solubility | Soluble to 1 mg/ml in water |
| | UFP-101 Usage And Synthesis |
| Uses | UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 shows antidepressant-like effect[1][2]. | | in vivo | UFP-101 elicits a pronounced acute and dosedependent antidepressant-like effect in mice submitted to the forced swimming test (FST)[1]. | | IC 50 | NOP Receptor/ORL1 | | storage | Store at -20°C | | References | [1] Calo G, et al. [Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002;136(2):303-311. DOI:10.1038/sj.bjp.0704706
[2] Gavioli EC, et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci. 2003;17(9):1987-1990. DOI:10.1046/j.1460-9568.2003.02603.x |
| | UFP-101 Preparation Products And Raw materials |
|